Fycompa

This site is for EU Healthcare professionals only

Fycompa® (perampanel)

is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.

Fycompa® (perampanel)

is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy
This site has been established to provide healthcare professionals with basic information on Fycompa. Please feel free to contact our medical information department should you have any requests or enquiries relating to Fycompa or Eisai by emailing EUMedInfo@eisai.net

About Fycompa

Fycompa (perampanel) is a selective, non-competitive AMPA receptor antagonist discovered by the research teams at Eisai laboratories. The development of an AMPA antagonist compound with a favourable pharmacokinetic and safety profile arose after the AMPA receptor was identified as a promising target for drug development. The AMPA receptor is widely present in almost all excitatory neurons. It is believed to play a role in a large number of central nervous system diseases with similar neuropathology.

Adverse events should be reported to Eisai, click here for contact details